
Stocks are mixed and S&P 500 hovers near record high as Washington and Beijing discuss trade
US stocks were mixed on Monday and the S&P 500 approached an all-time high as trade talks between the US and China kicked off in London.
The Dow fell 75 points. The broader S&P 500 was flat and the tech-heavy Nasdaq Composite gained 0.15%. Stocks were relatively unchanged as investors monitored developments from the trade talks.
The S&P 500 on Friday hit its highest level since February and was less than 2.4% away from hitting a new record high.
The Dow, S&P 500 and Nasdaq are coming off of back-to-back weeks of gains. The US stock market has steadily rallied in the last two months as President Donald Trump has softened his initial plan for sweeping tariffs. After the S&P 500 tumbled to the precipice of a bear market in early April, the index has rallied more than 20%.
'Markets have moved higher on tariff postponement and the perception that they will be more moderate than initially announced,' said Richard Saperstein, chief investment officer at Treasury Partners. 'We expect markets to remain headline sensitive, as trade deals take time to negotiate and unsettling tariff news is likely to cause noticeable volatility.'
Wall Street last week rallied on optimistism about a potential thaw in trade tensions between the United States and China. The meeting on Monday between representatives from Washington and Beijing comes after Trump and Chinese President Xi Jinping spoke by phone on Thursday.
The S&P 500's ascent towards a record high comes after a year of wild swings. Wall Street this year has been shaken by historic levels of uncertainty and volatility as Trump has gone back and forth on tariffs.
The S&P 500 slumped in March and early April as Trump rolled out his plan for massive tariffs, hitting its lowest level of the year on April 8. The market then steadily regained ground since as Trump softened his approach and paused most tariffs.
Markets have also received a boost from relatively strong economic data that has soothed nerves about how the economy has been holding up during the early stages of Trump's tariff regime. Investors this week will be attuned to new inflation data for the month of May.
The S&P 500's record high of 6,144.15 was set on February 19. The benchmark index fell as low as 4,982.77 on April 8, about 18.9% below that high, before staging a remarkable recovery.
Wall Street banks this year have have slashed and then raised their year-end projections for the S&P 500 as shifts in trade policy and surprisingly strong economic data have changed the outlook for markets.
Goldman Sachs in May raised its year-end target for the S&P 500 to 6,100 after the bank had previously cut its target twice this year. UBS in May raised its target to 6,000 after similarly having cut it earlier in the year.
Other banks have taken note, too. Deutsche Bank last week raised its year-end target to 6,550 after also having cut it earlier. JPMorgan Chase on Thursday raised its year-end target to 6,000 after a previous cut. The S&P 500 is trading just above 6,000 as of Monday.
'The earnings outlook has been sensitive to policy decisions to an unprecedented degree, specifically on tariffs,' analysts at Deutsche Bank said in a June 2 note. 'We now see the tariff drag at only about one-third of what we previously penciled in.'
Sam Stovall, chief investment strategist at CFRA Research, said in a Monday note that if the S&P 500 eclipses a new record high, it will officially end the correction that the index entered on March 13, when it had just fallen 10% from its February high. A correction is a Wall Street term for falling 10% from a record high.
Historically, the S&P 500 has risen an average of 10% over the next 127 days at the conclusion of a correction, according to Stovall. 'Meaningful, extended gains are not assured, however,' he said.
'Absent major policy surprises, the path of least resistance is to new highs,' analysts at JPMorgan Chase said in a Thursday note.
This is a developing story and will be updated.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
26 minutes ago
- Business Upturn
Stocks to watch on June 12: Tata Comm, Max Health, Dr Reddy's, HDFC Life, PayTM in focus on brokerage views
By News Desk Published on June 12, 2025, 08:17 IST Several brokerages have released their latest views and price targets on key listed companies. Here are the highlights of fund house recommendations for the day: CLSA on Tata Communications: Maintain Outperform on the company, target price at Rs 2100 per share Jefferies on Max Healthcare: Maintain Buy on the company, target price at Rs 1400 per share Nomura on Dr Reddy's: Maintain Buy on the company, target price at Rs 1575 per share Morgan Stanley on Life Insurance sector: Individual new sum assured growth stronger than individual APE for most large players HSBC on AMCs: SIP flows up, lump sum flows weak. Valuations of AMCs are now at peak Goldman Sachs on HDFC Life: Expect moderate H1 growth followed by a pickup in H2, target price at Rs 830 per share Citi on HCL Technologies: Maintain Neutral on the company, target price at Rs 1510 per share Citi on Britannia: Maintain Buy on the company, target price at Rs 5645 per share Citi on Hindustan Zinc: Maintain Sell on the company, target price at Rs 400 per share UBS on PayTM: Maintain Neutral on the company, target price at Rs 1000 per share Goldman Sachs on United Spirits: Maintain Buy on the company, target price at Rs 1700 per share Macquarie on United Spirits: Maintain Underperform on the company, target price at Rs 1250 per share Disclaimer: This update is for informational purposes only and does not constitute investment advice. Investors should consult certified financial advisors before making any investment decisions. News desk at


Business Upturn
26 minutes ago
- Business Upturn
Paytm shares in focus today as government dismisses reports on MDR charges for UPI, UBS says negative for stock
Shares of One97 Communications Ltd (Paytm) will be in focus today after the Ministry of Finance issued a strong denial of recent reports suggesting that the government was planning to introduce Merchant Discount Rate (MDR) on Unified Payments Interface (UPI) transactions. By Markets Desk Published on June 12, 2025, 08:24 IST Shares of One97 Communications Ltd (Paytm) will be in focus today after the Ministry of Finance issued a strong denial of recent reports suggesting that the government was planning to introduce Merchant Discount Rate (MDR) on Unified Payments Interface (UPI) transactions. In an official statement, the ministry termed such claims as 'completely false, baseless, and misleading', adding that they create 'needless uncertainty, fear and suspicion' among citizens. It reiterated the government's commitment to promoting digital payments through UPI and clarified that there are no plans to levy MDR on these transactions. The clarification comes after multiple reports circulated online claiming that the government was considering levying MDR on large-ticket UPI payments. MDR is a fee charged by banks to merchants for real-time payment processing. While MDR is still applicable on card transactions in some segments, it was waived for UPI and RuPay card payments in 2020 to encourage digital adoption. The market has closely tracked these developments, especially due to the potential impact on fintech players such as Paytm, which operate at scale in the UPI ecosystem. Brokerage UBS, in a note on One97 Communications, said: 'The Ministry of Finance in a tweet has refuted reports claiming introduction of MDR on UPI. Delay or non-introduction of MDR is sentimentally negative for Paytm.' UBS has a 'Neutral' rating on the stock with a target price of ₹1,000. The absence of MDR continues to limit monetisation opportunities for UPI players like Paytm, which had earlier indicated that policy clarity on MDR would be a key driver for its payments profitability roadmap. Disclaimer: The views and target prices mentioned are as stated by UBS and do not represent the opinions or recommendations of this publication. Investors are advised to consult their financial advisors before making any investment decisions. Markets Desk at